Tretinoin face-cream options: compare the name, formula and supply record

Smooth Move’s product record identifies a compounded cream with tretinoin, niacinamide and vitamin C. No active percentages, complete base or confirmed supplied quantity were established from the inspected pages. These gaps should remain visible alongside the offer, rather than being filled from an unrelated tretinoin label.

Its current plans list twelve months for $504, six for $300, three for $168 and one for $70. Corresponding monthly displays are $42, $49.99, $55.99 and $69.99. The Smooth Move review distinguishes those commercial terms from actual dispensing and clinical duration. Cancellation wording alone does not settle what happens after an order is processed.

Agency’s current product page calls this offer Night Renew Rx and displays 24 g as a 60-day supply. The potential ingredient list is broader than tretinoin alone, and a prominent qualification says not every formula contains tretinoin. Its safety information describes a compounded preparation with no single fixed formula.

The pricing record lists $130 per subscription order, free shipping and applicable taxes, with automatically scheduled 60-day shipments. One consultation credit is included per shipment; additional consultations are listed at $10. Our Agency review explains why a known package size still does not establish an individual’s ingredients or a universal treatment routine.

The current Hers page presents Anti-Aging Rx Cream. Its dedicated safety record identifies a compounded tretinoin, niacinamide and azelaic acid treatment. This is a different combination from Smooth Move and should not inherit specifications from the separate Hers Acne Cream.

We did not establish a current all-in price, package quantity or billing period for the anti-aging offer without proceeding into an assessment. The Hers review leaves those fields unresolved. A public evaluation link is not a complete quote, and the existence of a product page is not confirmation that a prescription will be offered to any particular visitor.

Ingredient strength describes only part of a preparation. The carrier, other actives and the complete ingredient list remain relevant to identifying what has been prescribed. A higher percentage is not a score for better results, and a more elaborate mixture is not automatically more comfortable or effective.

The vehicle guide uses exact-product records to explain those fields. RENOVA’s label, for example, identifies its own 0.02% oil-in-water cream and a narrow adjunctive fine-wrinkle indication. That label is not evidence that one of these personalized combinations is equivalent, available in stock or approved. The comparison concerns public documentation, not substitution between medicines.

A provider can explain a prescription; a pharmacy can explain the preparation it dispenses; an account-support team can answer commercial questions. Websites may place those functions close together, but they do not become interchangeable. An ingredient list is not a guarantee of clinical access, and a messaging promise does not verify a container’s contents.

Agency publishes a consultation-credit model. Hers’ terms distinguish the platform, medical groups and pharmacies. CoreAge’s offer likewise separates professional entities from administration. None of those descriptions was tested as a patient journey here. The dispensing-record article provides a way to formulate questions without implying that the services already coordinated someone’s care.

CoreAge’s multiple advertised plan lengths, Agency’s stated 24 g order and Hers’ unconfirmed package terms cannot support a meaningful cost-per-application calculation. Even where a quantity is published, that does not tell this publication how much a reader is prescribed, what a delivery contains or which date governs its use.

Published subscription language also needs its conditions. Agency’s order price includes a specific consultation-credit allowance rather than unlimited separate consultations. Hers’ general terms describe recurring services, but the exact chosen product’s billing arrangement still needs confirmation. Neither a lower starting figure nor a longer supply description establishes a favorable clinical choice. The complete charge and the actual preparation remain separate records to understand.

FDA’s compounding explanation makes the approval distinction clear: custom preparations do not undergo the same premarket verification as approved drugs. Research on an ingredient or another cream cannot complete the missing evidence for a whole mixture. The combination guide develops that point without dismissing a legitimate clinical reason for an individual prescription.

A useful outcome from this comparison is an accurate name, a clear list of what is proposed and a practical contact for unresolved questions. It is not a product ranking based on assumed gentleness, ingredient count or advertising. Questions about symptoms and treatment decisions remain with qualified professionals, rather than a commercial shortlist.